Zimmer Biomet Holdings, Inc. (ZBH) Bundle
Understanding Zimmer Biomet Holdings, Inc. (ZBH) Revenue Streams
Understanding Zimmer Biomet Holdings, Inc.’s Revenue Streams
Zimmer Biomet Holdings, Inc. reported the following net sales for the three and nine-month periods ended September 30, 2024:
| Period | United States (in millions) | International (in millions) | Total Net Sales (in millions) | Year-over-Year Growth (%) |
|---|---|---|---|---|
| Three Months | $1,052.3 | $771.9 | $1,824.2 | 4.0% |
| Nine Months | $3,257.7 | $2,397.7 | $5,655.4 | 3.7% |
The year-over-year revenue growth was driven by various factors, including market growth and new product introductions. However, the transition to a new enterprise resource planning (ERP) system in July 2024 impacted operational capabilities, particularly in fulfilling customer orders.
Revenue Breakdown by Product Category
Net sales by product category for the three and nine-month periods ended September 30, 2024, are as follows:
| Product Category | Three Months 2024 (in millions) | Three Months 2023 (in millions) | Change (%) | Nine Months 2024 (in millions) | Nine Months 2023 (in millions) | Change (%) |
|---|---|---|---|---|---|---|
| Knees | $745.1 | $706.3 | 5.5% | $2,334.3 | $2,240.1 | 4.2% |
| Hips | $481.5 | $465.3 | 3.5% | $1,479.1 | $1,462.5 | 1.1% |
| S.E.T. | $454.2 | $423.2 | 7.3% | $1,376.4 | $1,299.3 | 5.9% |
| Other | $143.4 | $158.8 | (9.7%) | $465.6 | $452.2 | 3.0% |
The S.E.T. category includes sales from Sports Medicine, Extremities, Trauma, Craniomaxillofacial, and Thoracic products. The growth in the Knees and S.E.T. categories was particularly notable, while the Other category saw a decline in the three-month period.
Geographic Revenue Contribution
Net sales by geography for the three and nine-month periods ended September 30, 2024, are detailed below:
| Geography | Three Months 2024 (in millions) | Three Months 2023 (in millions) | Change (%) | Nine Months 2024 (in millions) | Nine Months 2023 (in millions) | Change (%) |
|---|---|---|---|---|---|---|
| United States | $1,052.3 | $1,031.4 | 2.0% | $3,257.7 | $3,160.6 | 3.1% |
| International | $771.9 | $722.2 | 6.9% | $2,397.7 | $2,293.5 | 4.5% |
The international segment outperformed the domestic segment in terms of growth rate in both the three-month and nine-month periods, reflecting strong market demand across various regions.
Significant Changes in Revenue Streams
In 2024, the company faced operational challenges primarily due to the ERP implementation, which negatively affected its ability to fulfill customer orders. This disruption is expected to have a less than one percent impact on total net sales for the year. Additionally, foreign currency exchange rates contributed to a decline of 0.1% and 1.1% in net sales for the three and nine-month periods, respectively.
A Deep Dive into Zimmer Biomet Holdings, Inc. (ZBH) Profitability
A Deep Dive into Zimmer Biomet Holdings, Inc. Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was 71.6%, compared to 71.7% for the same period in 2023.
Operating Profit Margin: The operating profit margin for the same nine-month period was 15.9%, down from 16.9% in 2023.
Net Profit Margin: The net profit margin for the nine months ended September 30, 2024, was 11.8%, compared to 11.1% for the same period in the previous year.
Trends in Profitability Over Time
Net earnings increased to $665.1 million in the nine months ended September 30, 2024, from $604.8 million in the same period of 2023, reflecting a growth of 10.6%.
In the three-month period ended September 30, 2024, net earnings reached $249.1 million compared to $162.7 million in the same period of 2023, representing a 53.1% increase.
Comparison of Profitability Ratios with Industry Averages
The industry average gross profit margin for the medical devices sector is approximately 65%, indicating that the company outperforms this benchmark with a gross margin of 71.6%.
Operating profit margins in the industry average around 15%, which aligns with the company's margin of 15.9%.
The net profit margin industry average is about 10%, showing that the company’s net profit margin of 11.8% is above average.
Analysis of Operational Efficiency
The cost of products sold as a percentage of net sales was 29.5% for the three months ended September 30, 2024, slightly down from 29.6% in the prior year.
For the nine months ended September 30, 2024, the cost of products sold was 28.4%, compared to 28.3% the previous year, indicating stable cost management.
| Metric | 2024 Q3 | 2023 Q3 | Change (%) |
|---|---|---|---|
| Gross Profit Margin | 71.6% | 71.7% | -0.1% |
| Operating Profit Margin | 15.9% | 16.9% | -1.0% |
| Net Profit Margin | 11.8% | 11.1% | +0.7% |
| Cost of Products Sold (% of Net Sales) | 29.5% | 29.6% | -0.1% |
Research and Development Expenses: R&D expenses decreased to 5.8% of net sales for the nine months ended September 30, 2024, compared to 6.3% in the prior year.
Selling, General and Administrative Expenses: SG&A expenses as a percentage of net sales increased to 38.6% for the nine months ended September 30, 2024, from 38.8% in 2023.
Debt vs. Equity: How Zimmer Biomet Holdings, Inc. (ZBH) Finances Its Growth
Debt vs. Equity: How Zimmer Biomet Holdings, Inc. Finances Its Growth
As of September 30, 2024, the total outstanding debt for the company was $6,450.7 million, with $1,713.0 million classified as current debt. The current debt includes $850.0 million of senior notes maturing on November 22, 2024, and $863.0 million maturing on April 1, 2025.
Debt-to-Equity Ratio and Industry Comparison
The debt-to-equity ratio as of September 30, 2024, was approximately 0.52, calculated using total debt of $6,450.7 million and total stockholders' equity of $12,383.2 million. This ratio is below the industry average, indicating a lower reliance on debt financing compared to peers in the medical devices sector, which typically ranges from 0.6 to 1.0.
Recent Debt Issuances and Refinancing Activity
In August 2024, the company completed the offering of $700.0 million in senior notes due September 15, 2034, with an interest rate of 5.200%. Additionally, the company entered into a new five-year revolving credit agreement of $1.5 billion in June 2024.
Balancing Debt Financing and Equity Funding
The company has maintained a strategic balance between debt and equity funding. In May 2024, a $2.0 billion share repurchase program was authorized, with $1,308.1 million remaining available as of September 30, 2024. Cash flows provided by operating activities for the nine months ended September 30, 2024, totaled $993.1 million, which supports ongoing liquidity needs.
| Debt Type | Amount (in millions) | Maturity Date | Interest Rate |
|---|---|---|---|
| Senior Notes | $850.0 | November 22, 2024 | N/A |
| Senior Notes | $863.0 | April 1, 2025 | N/A |
| 5.200% Senior Notes | $700.0 | September 15, 2034 | 5.200% |
| Revolving Credit Facility | $1,500.0 | June 28, 2029 | Variable |
Overall, the company continues to optimize its capital structure, leveraging both debt and equity to finance growth while maintaining a manageable debt level relative to its equity base.
Assessing Zimmer Biomet Holdings, Inc. (ZBH) Liquidity
Assessing Liquidity and Solvency
As of September 30, 2024, the liquidity position of the company is evaluated through its current and quick ratios. The current ratio stands at 1.92, indicating a strong ability to cover short-term liabilities. The quick ratio, which excludes inventory from current assets, is recorded at 1.23, reflecting a solid liquidity position even when considering only the most liquid assets.
Working Capital Trends
The working capital as of September 30, 2024, is approximately $3.3 billion, a slight increase from $3.1 billion at the end of 2023. This upward trend in working capital suggests improved operational efficiency and better management of current assets and liabilities.
| Date | Current Assets ($M) | Current Liabilities ($M) | Working Capital ($M) |
|---|---|---|---|
| January 1, 2024 | 10,384.5 | 7,562.3 | 2,822.2 |
| September 30, 2024 | 10,903.7 | 7,610.7 | 3,293.0 |
Cash Flow Statements Overview
The cash flow from operating activities for the nine-month period ending September 30, 2024, is reported at $993.1 million, which is consistent with $993.2 million in the prior year. This stability indicates that the company is maintaining its cash-generating ability from core operations.
Cash flows used in investing activities totaled $596.9 million, compared to $558.1 million in the previous year. The increase is attributed to ongoing investments in product development and acquisitions.
Cash flows used in financing activities were $243.9 million in the nine-month period ending September 30, 2024, a decrease from $512.1 million in the same prior year period. This reduction is primarily due to the issuance of senior notes totaling $700 million used to repurchase common stock and repay debts.
| Cash Flow Type | 2024 ($M) | 2023 ($M) |
|---|---|---|
| Operating Activities | 993.1 | 993.2 |
| Investing Activities | (596.9) | (558.1) |
| Financing Activities | (243.9) | (512.1) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company holds $569 million in cash and cash equivalents, with an additional $1 billion available under its 364-Day Credit Agreement and $1.5 billion under its Five-Year Revolving Facility. This substantial liquidity provides a buffer against potential operational challenges or unexpected market conditions.
However, the company has a significant outstanding debt of $6.45 billion, with $1.71 billion classified as current debt. Notably, $850 million of senior notes are due in November 2024 and $863 million in April 2025. The ability to meet these obligations will depend on continued strong cash flows from operations.
In summary, while liquidity metrics indicate a robust position, the substantial debt obligations and upcoming maturities warrant careful monitoring to ensure solvency.
Is Zimmer Biomet Holdings, Inc. (ZBH) Overvalued or Undervalued?
Valuation Analysis
Analyzing the valuation metrics of the company reveals critical insights for investors. The primary ratios used in assessing valuation include the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio.
Price-to-Earnings (P/E) Ratio
The current P/E ratio stands at 33.5. This indicates that investors are willing to pay $33.50 for every dollar of earnings, reflecting a premium valuation compared to industry peers.
Price-to-Book (P/B) Ratio
The P/B ratio is recorded at 3.6. This suggests the stock is trading at a significant premium over its book value, which is indicative of investor expectations for future growth.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is currently 18.2. This reflects a moderate valuation level, suggesting that the company is relatively fairly valued in relation to its earnings before interest, taxes, depreciation, and amortization.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $95.00 and a high of $120.00. As of the latest trading day, the stock is priced at $110.50, which represents a 5.2% increase year-to-date.
Dividend Yield and Payout Ratios
The current dividend yield is 0.87%, with a payout ratio of 24%. This indicates a conservative approach to returning capital to shareholders while retaining a significant portion of earnings for reinvestment.
Analyst Consensus
Analyst consensus currently rates the stock as a Hold, with a price target of $115.00. This reflects a cautious outlook based on the company’s growth prospects and current valuation metrics.
| Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 33.5 |
| Price-to-Book (P/B) Ratio | 3.6 |
| Enterprise Value-to-EBITDA (EV/EBITDA) Ratio | 18.2 |
| 52-Week Low | $95.00 |
| 52-Week High | $120.00 |
| Current Stock Price | $110.50 |
| Dividend Yield | 0.87% |
| Payout Ratio | 24% |
| Analyst Consensus | Hold |
| Price Target | $115.00 |
Key Risks Facing Zimmer Biomet Holdings, Inc. (ZBH)
Key Risks Facing Zimmer Biomet Holdings, Inc.
The financial health of Zimmer Biomet Holdings, Inc. is influenced by various internal and external risks. These risks can significantly impact the company's performance and shareholder value.
Overview of Internal Risks
Internal risks include operational disruptions, product recalls, and management changes. As noted in the latest earnings report, the transition to a new enterprise resource planning (ERP) system in July 2024 led to operational challenges that affected the ability to fulfill customer orders. This disruption had a negative impact on U.S. net sales and also delayed shipments to international affiliates.
Overview of External Risks
External risks encompass industry competition, regulatory changes, and market conditions. The medical device industry is characterized by intense competition and rapid technological advancement. The company faces pressure from competitors in pricing and innovation. Additionally, ongoing regulatory scrutiny, especially regarding compliance with the European Union Medical Device Regulation (EU MDR), poses a challenge.
Financial and Strategic Risks
In terms of financial risks, Zimmer Biomet reported outstanding debt of $6,450.7 million as of September 30, 2024, with $1,713.0 million classified as current debt. Notably, $850.0 million of senior notes are due on November 22, 2024, and $863.0 million are due on April 1, 2025. The company believes it can meet these obligations through operational cash flow, new debt issuance, or borrowing against credit facilities.
Strategic risks arise from the company's restructuring plans, which aim to optimize costs. The 2023 Restructuring Plan is expected to incur total pre-tax charges of approximately $120 million. These restructuring efforts may lead to short-term operational disruptions but are intended to enhance long-term efficiency.
Mitigation Strategies
To mitigate these risks, the company has initiated a global restructuring program aimed at reducing gross annual pre-tax operating expenses by $175 million to $200 million by the end of 2025. Additionally, the company is focused on improving its product pipeline and enhancing customer service to regain market share lost due to operational challenges.
| Risk Category | Description | Current Financial Impact |
|---|---|---|
| Operational Risks | ERP system transition causing fulfillment delays | Negative impact on U.S. net sales |
| Financial Risks | Outstanding debt obligations | Debt of $6,450.7 million; $1,713.0 million current |
| Regulatory Risks | Compliance with EU MDR | Increased costs and potential delays in product approvals |
| Market Risks | Intense competition and pricing pressure | Pressure on margins and market share |
| Strategic Risks | Restructuring plan costs | Pre-tax charges of approximately $120 million |
Future Growth Prospects for Zimmer Biomet Holdings, Inc. (ZBH)
Future Growth Prospects for Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. is positioned for growth through several key drivers:
Analysis of Key Growth Drivers
- Product Innovations: The company has introduced several new products in its Knees, Hips, and Sports Medicine categories. For the nine-month period ending September 30, 2024, net sales for Knees were $2,334.3 million, an increase of 4.2% from $2,240.1 million in the same period of 2023.
- Market Expansions: International sales increased by 6.9% and 4.5% during the three and nine-month periods ending September 30, 2024, respectively, compared to the prior year.
- Acquisitions: The acquisition of OrthoGrid Systems, Inc. in late 2024 enhances its surgical assistance capabilities.
Future Revenue Growth Projections
The company anticipates mid-single-digit percentage revenue growth for 2024, driven by market expansion and new product launches. The expected negative impact from foreign currency exchange rates is approximately 0.75% on full-year 2024 sales.
Earnings Estimates
For the nine-month period ending September 30, 2024, net earnings were $664.3 million compared to $604.8 million for the same period in 2023.
Strategic Initiatives and Partnerships
- ERP Implementation: The transition to a new ERP system is expected to improve operational efficiency and customer order fulfillment, with a projected less than 1% impact on net sales for 2024.
- Restructuring Plans: Ongoing restructuring initiatives are projected to yield annual pre-tax operating expense reductions of $175 million to $200 million by the end of 2025.
Competitive Advantages
The company benefits from a diverse product portfolio and strong brand recognition within the orthopedic market. Its focus on innovation and strategic acquisitions positions it well against competitors. The Americas region accounted for $3,521.7 million in net sales during the nine-month period ending September 30, 2024.
| Financial Metric | 2024 (9-Months) | 2023 (9-Months) | Percentage Change |
|---|---|---|---|
| Net Sales (Total) | $5,655.4 million | $5,454.1 million | 3.7% |
| Net Earnings | $664.3 million | $604.8 million | 9.8% |
| Knees Sales | $2,334.3 million | $2,240.1 million | 4.2% |
| Hips Sales | $1,479.1 million | $1,462.5 million | 1.1% |
| S.E.T. Sales | $1,376.4 million | $1,299.3 million | 5.9% |
Overall, the company's strategic initiatives, product innovations, and market expansions are set to provide a robust foundation for future growth.
Zimmer Biomet Holdings, Inc. (ZBH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Zimmer Biomet Holdings, Inc. (ZBH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Zimmer Biomet Holdings, Inc. (ZBH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Zimmer Biomet Holdings, Inc. (ZBH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.